Bioheart expands venture round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Bioheart
|
$19 million
|
Advent-Morro Equity Partners |
Researchers are focused on a myogenic cell composition made up of adult muscle repair cells called myoblasts to repair damaged heart muscles. |
|
Pervasis Therapeutics
|
$12 million
|
Highland Capital Partners |
Researchers are at work integrating biomaterials with cells and drugs. |
|
Newron Pharmaceuticals
|
€7 million
|
TVM |
Newron is involved in the ongoing phase III clinical development of Safinamide for the treatment of Parkinson's disease and phase II development of Ralfinamide for neuropathic pain. |
|
BioLineRx
|
$9 million
|
Giza Venture Capital, Pitango Venture Capital, Teva Pharmaceuticals Industries |
BioLineRx plans to move BL-1020 for schizophrenia into human clinical trials in the first quarter of 2006. |
|
Tessera
|
$8.5 million
|
undisclosed |
Tessera has been developing tests for the early detection of prostate and colon cancer. |